Nursing(Degree) · First Year · NUR101
Anatomy and Physiology
Anatomy and Physiology is one of the most important foundation courses for nursing students in Zambia. This course helps you understand how the human body is structured and how it functions, from major organs to body systems such as the nervous, cardiovascular, respiratory, and digestive …
Read more
Anatomy and Physiology is one of the most important foundation courses for nursing students in Zambia. This course helps you understand how the human body is structured and how it functions, from major organs to body systems such as the nervous, cardiovascular, respiratory, and digestive systems. A strong grasp of this subject is essential for exams set by nursing schools and regulatory bodies in Zambia. At 25schools, we simplify complex anatomy concepts using exam-focused questions, diagrams, and clear explanations designed for nursing exams. Whether you are preparing for tests, assignments, or final examinations, this course builds the clinical understanding every successful nurse needs. Start studying with 25schools today and gain the confidence to excel in anatomy and physiology exams.
-
Coming soon
Topic 136Coming soon
Osteoarthritis: Degenerative Joint Disease
This comprehensive rheumatology topic provides Zambian tertiary nursing and medical students with detailed understanding of osteoarthritis (OA)—the most common joint disorder worldwide, representing a complex, multifactorial disease of the entire synovial joint organ involving articular cartilage degradation, subchondral bone remodeling, osteophyte formation, synovial inflammation, and periarticular muscle weakness. For Zambian healthcare students preparing for examinations in internal medicine, orthopaedics, rheumatology, and medical-surgical nursing, mastery of OA is essential given its increasing prevalence with aging populations, its position as the leading cause of disability in older adults, and the significant burden it places on Zambian healthcare resources in both urban and rural settings. The traditional conceptualization of OA as a simple 'wear and tear' disease of articular cartilage has been supplanted by a modern understanding of OA as a dynamic, metabolically active process involving the entire joint organ, with complex interactions between mechanical, inflammatory, and metabolic factors. Articular cartilage is a specialized, avascular, aneural connective tissue composed of extracellular matrix (primarily type II collagen and aggrecan) maintained by a sparse population of chondrocytes. In early OA, chondrocytes initially proliferate and increase matrix synthesis in a failed reparative response, but ultimately undergo phenotypic shift, producing matrix-degrading enzymes (matrix metalloproteinases, aggrecanases) and inflammatory cytokines (IL-1β, TNF-α) while reducing matrix synthesis. This catabolic imbalance progressively depletes aggrecan (causing cartilage softening and increased water content) and disrupts the collagen network (causing fibrillation, fissuring, and eventual full-thickness cartilage loss). Concurrently, subchondral bone undergoes dramatic remodeling: increased turnover, sclerosis, cyst formation, and vascular invasion into the calcified cartilage. Marginal osteophytes—bony outgrowths at joint margins—represent attempted joint stabilization. Synovium shows variable, often mild, inflammatory infiltrate. The biomechanical consequences are progressive joint failure. Risk factors are categorized as systemic (age, female sex, genetics, estrogen status) and local (obesity, joint injury, occupational/recreational overuse, malalignment, muscle weakness). Age is the strongest risk factor, reflecting cumulative mechanical exposure, age-related chondrocyte senescence, and declining synthetic capacity. Obesity increases OA risk through both mechanical overload and systemic metabolic effects (adipokine-mediated inflammation). Prior joint injury—particularly meniscal and cruciate ligament tears—markedly accelerates OA development. Genetic factors contribute 40-60% of susceptibility, with multiple loci identified (GDF5, COL2A1, FRZB). Clinical presentation is typically insidious, with gradual onset of deep, aching joint pain exacerbated by weight-bearing activity and relieved by rest. Morning stiffness is brief (<30 minutes) and 'gelling' phenomenon occurs after inactivity. As disease progresses, pain becomes more constant and occurs at night. Functional limitations develop sequentially: difficulty with walking, climbing stairs, rising from chairs. Physical examination reveals bony enlargement (osteophytes), crepitus with motion, limited range of motion, joint line tenderness, and varus or valgus malalignment. Joint effusion may be present but is typically mild. The classic distribution involves hands (distal interphalangeal—Heberden's nodes, proximal interphalangeal—Bouchard's nodes, first carpometacarpal), knees (medial tibiofemoral and patellofemoral compartments), hips, and spine (apophyseal joints, discovertebral junctions). This pattern distinguishes OA from rheumatoid arthritis (MCP, wrist, MTP involvement). Diagnosis is primarily clinical, supported by characteristic radiographic findings: non-uniform joint space narrowing, subchondral sclerosis, subchondral cysts, and marginal osteophytes. Radiographic severity is graded by Kellgren-Lawrence scale (0-4), though radiographic findings correlate only modestly with symptoms. Laboratory studies are normal (normal ESR, CRP, negative rheumatoid factor), useful primarily to exclude inflammatory arthropathies. Synovial fluid analysis, if performed, reveals non-inflammatory fluid (WBC <2000/mm³). Management is multimodal, individualized, and sequenced according to symptom severity and functional impact. Core non-pharmacological interventions are first-line and foundational: patient education and self-management programs, weight loss (5-10% body weight produces significant symptomatic benefit), exercise therapy (low-impact aerobic, strengthening, and range-of-motion), physical therapy (gait aids, bracing, orthotics), and occupational therapy (activity modification, assistive devices). Pharmacological therapy begins with acetaminophen (paracetamol) for mild pain, though efficacy is modest. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) are effective for moderate-severe pain but require careful consideration of gastrointestinal, cardiovascular, and renal risks, with lowest effective dose and shortest duration. Topical NSAIDs and capsaicin are effective for hand and knee OA with minimal systemic exposure. Intra-articular corticosteroids provide rapid, potent but temporary (4-8 weeks) relief for acute flares with effusion. Intra-articular hyaluronic acid (viscosupplementation) remains controversial with inconsistent evidence. Weak opioids (tramadol) are reserved for refractory pain when contraindications or failure of other analgesics. Duloxetine is effective for chronic OA pain. Glucosamine and chondroitin are not recommended (ineffective in high-quality trials). Advanced disease with persistent pain and functional limitation despite comprehensive conservative management warrants surgical intervention. Total joint arthroplasty (hip, knee) is highly effective, providing dramatic pain relief and functional improvement with excellent long-term survival (>90% at 10-15 years). Unicompartmental knee arthroplasty, osteotomy, and arthroscopic debridement have selective indications. For Zambian clinicians, specific challenges include limited access to joint replacement surgery (concentrated in tertiary centers with long waiting lists), affordability of chronic NSAID therapy, availability of physical and occupational therapy services, and need for culturally-adapted patient education materials. Prevention strategies targeting modifiable risk factors are paramount: obesity prevention and weight management, injury prevention (workplace ergonomics, sports safety), and muscle strengthening programs, particularly for aging populations. For Zambian nurses and clinicians, comprehensive OA knowledge enables accurate diagnosis and distinction from inflammatory arthropathies, structured implementation of evidence-based non-pharmacological interventions, rational sequencing of pharmacological therapy with attention to comorbidity and risk, appropriate timing of surgical referral, and culturally-sensitive patient education promoting self-management—ultimately reducing pain, preserving function, and maintaining quality of life for the growing number of Zambians living with this highly prevalent condition.
-
Coming soon
Topic 137Coming soon
Rheumatoid Arthritis: Autoimmune Synovitis
This comprehensive rheumatology topic provides Zambian tertiary nursing and medical students with detailed understanding of rheumatoid arthritis (RA)—a chronic, systemic, autoimmune inflammatory disorder primarily targeting synovial joints, characterized by symmetric polyarthritis, progressive joint destruction, and diverse extra-articular manifestations, associated with substantial morbidity, disability, and premature mortality if inadequately treated. For Zambian healthcare students preparing for examinations in internal medicine, rheumatology, immunology, and medical-surgical nursing, mastery of RA is essential given its global prevalence of 0.5-1%, its potential for complete clinical remission with modern early, targeted therapy, and the unique diagnostic and management challenges in the Zambian context where infectious mimics are common, rheumatology specialist access is extremely limited, and biologic disease-modifying antirheumatic drugs (DMARDs) are largely unavailable. The immunopathology of RA is complex and unfolds over years, with an asymptomatic phase of autoimmunity preceding clinical synovitis. Genetic susceptibility is conferred primarily by HLA-DRB1 alleles encoding the 'shared epitope'—a conserved amino acid sequence in the peptide-binding groove that influences presentation of citrullinated antigens. Multiple environmental factors contribute: cigarette smoking is the strongest established risk factor (accounting for 25-35% of seropositive RA risk), acting synergistically with shared epitope genes; periodontal infection (Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans) may initiate citrullination of oral proteins; alterations in gut microbiome and pulmonary exposures are implicated. The critical initiating event is post-translational modification of self-proteins by peptidylarginine deiminase enzymes, converting arginine residues to citrulline. Citrullinated proteins—detectable in inflamed synovium, lung, and other tissues—are recognized as neoepitopes, triggering production of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF). This autoimmune response develops years before clinical arthritis (serologic phase). Transition to clinical synovitis involves loss of immune tolerance, expansion of autoreactive T and B cells, and localization of immune complexes to synovium. Established RA synovium is transformed into an invasive, tumor-like tissue—the pannus—characterized by massive infiltration of CD4+ T cells (Th1, Th17 phenotypes), activated B cells and plasma cells producing autoantibodies, macrophages secreting pro-inflammatory cytokines (TNF-α, IL-1, IL-6), and fibroblast-like synoviocytes acquiring an aggressive, matrix-degrading phenotype. This inflammatory milieu drives angiogenesis, leukocyte recruitment, and activation of osteoclasts and chondrocytes. Cartilage destruction results from enzymatic degradation (matrix metalloproteinases, cathepsins) by activated synoviocytes and chondrocytes. Bone erosion occurs at the pannus-bone interface via RANKL-mediated osteoclast activation. Periarticular osteopenia results from cytokine suppression of osteoblast activity. Clinical presentation typically insidious over weeks to months, though acute-onset (hours to days) and palindromic (intermittent) variants occur. The cardinal feature is symmetric polyarthritis involving small joints of hands and feet: metacarpophalangeal (MCP), proximal interphalangeal (PIP), and metatarsophalangeal (MTP) joints. Wrists, knees, ankles, shoulders, elbows, and hips are commonly involved. The distal interphalangeal (DIP) joints and lumbar spine are typically spared—a key distinguishing feature from osteoarthritis and spondyloarthritis. Morning stiffness exceeds 60 minutes and improves with activity, reflecting inflammatory burden. Physical examination reveals warm, swollen, tender joints with synovitis palpable as boggy soft tissue swelling. Characteristic deformities develop with chronic disease: ulnar deviation at MCPs, swan-neck deformity (PIP hyperextension, DIP flexion), boutonnière deformity (PIP flexion, DIP hyperextension), 'Z'-deformity of thumb, and wrist subluxation. Extra-articular manifestations reflect systemic autoimmunity and predict increased mortality. Rheumatoid nodules (20-30%)—subcutaneous firm, nontender masses at extensor surfaces and pressure points—are associated with seropositivity and severe disease. Sjögren's syndrome (secondary, 10-25%) presents with keratoconjunctivitis sicca and xerostomia. Pulmonary involvement includes interstitial lung disease (usual interstitial pneumonia, nonspecific interstitial pneumonia), pleural effusion, and rheumatoid nodules. Cardiac manifestations include pericarditis, myocarditis, and accelerated atherosclerosis—RA is a coronary artery disease equivalent. Ocular involvement includes scleritis and peripheral ulcerative keratitis. Felty's syndrome (RA, splenomegaly, neutropenia) and large granular lymphocyte leukemia are associated with severe, long-standing disease. Vasculitis (rheumatoid vasculitis) is rare but serious, affecting small to medium vessels. Laboratory findings include normocytic anemia, thrombocytosis (reflecting inflammation), and acute phase reactants: ESR and CRP elevated, correlating with disease activity. Rheumatoid factor (RF)—autoantibody against IgG Fc—is positive in 70-80% but lacks specificity (5% healthy adults, chronic infections). Anti-citrullinated protein antibodies (ACPA) demonstrate 95% specificity and similar sensitivity, predict severe, erosive disease, and may be detected years before clinical onset. Antinuclear antibodies (ANA) positive in 30-40%. Synovial fluid analysis reveals inflammatory fluid (WBC 5,000-50,000, predominantly neutrophils). Radiographic findings evolve with disease duration: early findings are soft tissue swelling and periarticular osteopenia; established disease reveals symmetric joint space narrowing, marginal erosions (at 'bare areas' of intra-articular bone lacking cartilage), and subchondral cysts; late findings include deformities, subluxation, and secondary osteoarthritis. Ultrasound and MRI are more sensitive for detecting synovitis, tenosynovitis, and early erosions. Diagnosis is based on 2010 ACR/EULAR classification criteria, incorporating joint involvement, serology (RF, ACPA), acute phase reactants, and symptom duration. These criteria emphasize early diagnosis and treatment initiation. Differential diagnosis in Zambian practice requires particular attention to infectious mimics: HIV-associated arthritis (often oligoarticular, lower extremity predominant), viral arthritides (parvovirus B19, chikungunya, hepatitis B/C), and tuberculous arthritis (typically chronic monoarthritis). Crystal arthropathies (gout, pseudogout), systemic lupus erythematosus, psoriatic arthritis, and reactive arthritis must be distinguished. Management has been revolutionized by the paradigm of 'treat-to-target'—rapid escalation of therapy to achieve clinical remission or low disease activity, with regular objective assessment and medication adjustment. Disease-modifying antirheumatic drugs (DMARDs) are initiated immediately upon diagnosis. Methotrexate is the anchor drug (first-line, 7.5-25 mg weekly with folic acid supplementation), improving signs/symptoms and radiographic outcomes. Leflunomide and sulfasalazine are alternatives. Hydroxychloroquine is used for mild disease. Triple therapy (methotrexate + sulfasalazine + hydroxychloroquine) is effective and low-cost, particularly relevant for Zambian settings. Glucocorticoids (oral, intra-articular, intramuscular) provide rapid symptom control as bridging therapy while DMARDs take effect (4-12 weeks), but chronic use is minimized due to toxicity. Biologic DMARDs target specific inflammatory mediators: TNF inhibitors (etanercept, adalimumab, infliximab), IL-6 receptor inhibitors (tocilizumab), CTLA-4-Ig (abatacept), anti-CD20 (rituximab), and JAK inhibitors (tofacitinib, baricitinib) are highly effective but largely inaccessible in Zambian public health system. Non-pharmacological management includes patient education, physical and occupational therapy (range of motion, strengthening, joint protection, assistive devices), smoking cessation, cardiovascular risk management, and osteoporosis prevention (chronic inflammation and glucocorticoid use). Monitoring requires regular clinical assessment (28-joint Disease Activity Score—DAS28), laboratory monitoring for medication toxicity, and surveillance for complications. Prognosis is highly variable, but with modern treat-to-target strategies, remission is achievable in 40-60% of patients. Poor prognostic factors include high baseline disease activity, seropositivity (RF, ACPA), early erosions, and inadequate initial response. For Zambian clinicians, specific challenges include lack of rheumatology specialists (only a handful for entire country), limited access to diagnostic serology (RF, ACPA) and advanced imaging, unaffordability of biologic DMARDs, high prevalence of HIV and tuberculosis complicating immunosuppressive therapy, and need for context-appropriate treatment algorithms emphasizing methotrexate, low-dose corticosteroids, and hydroxychloroquine. Despite these challenges, substantial improvement in outcomes is achievable through early recognition, prompt methotrexate initiation, treat-to-target principles, and meticulous monitoring. For Zambian nurses and clinicians, comprehensive RA knowledge enables early diagnosis and distinction from endemic infectious mimics, initiation and monitoring of conventional DMARDs with appropriate safety surveillance, recognition of extra-articular manifestations and treatment complications, coordination of multidisciplinary non-pharmacological care, and provision of hope and education to patients facing a chronic, potentially disabling disease that is now eminently treatable.
-
Coming soon
Topic 138Coming soon
Gout: Crystal Arthropathy
This comprehensive rheumatology topic provides Zambian tertiary nursing and medical students with detailed understanding of gout—the most common inflammatory arthritis worldwide, caused by deposition of monosodium urate crystals in synovial joints and periarticular tissues in the setting of hyperuricemia, characterized by acute, excruciating, self-limiting flares, chronic tophaceous disease, and association with significant cardiometabolic comorbidity. For Zambian healthcare students preparing for examinations in internal medicine, rheumatology, nephrology, and primary care, mastery of gout is essential given its increasing prevalence in sub-Saharan Africa associated with nutritional transition, rising obesity rates, and epidemic of chronic kidney disease, as well as the availability of highly effective, low-cost, curative therapy that remains dramatically underutilized globally. Uric acid is the terminal product of purine metabolism in humans, who lack uricase—the enzyme that converts urate to soluble allantoin in most mammals. The serum urate concentration represents equilibrium between production (dietary purines, endogenous purine turnover) and excretion (primarily renal, 65-75%; intestinal, 25-35%). Hyperuricemia is defined biochemically as serum urate >6.8 mg/dL (404 μmol/L)—the saturation point at which extracellular fluid becomes supersaturated, creating risk for crystal formation. However, most hyperuricemic individuals never develop gout; additional factors including crystal nucleation, growth, and host inflammatory response determine clinical expression. The pathophysiology of acute gouty arthritis is a paradigm of autoinflammatory disease. Precipitating factors (rapid urate fluctuation, local trauma, cooling, dehydration) cause shedding of preformed urate crystals from articular deposits or de novo crystal formation. These needle-shaped, negatively birefringent crystals engage multiple pattern recognition receptors on synovial lining cells and resident macrophages. The NLRP3 inflammasome is central: crystal phagocytosis induces potassium efflux, lysosomal rupture, and cathepsin B release, activating the NLRP3 inflammasome complex, which cleaves procaspase-1 to active caspase-1, which cleaves pro-IL-1β to mature IL-1β. IL-1β orchestrates massive neutrophil recruitment through induction of endothelial adhesion molecules and chemokines (IL-8, CXCL1, CXCL2). Neutrophils phagocytose crystals, undergo respiratory burst, release proteases, and form extracellular traps—amplifying inflammation. This explosive cascade produces the cardinal features of acute gout: rapid-onset (peak 12-24 hours), excruciating pain, marked erythema, warmth, swelling, and disability, often simulating cellulitis or septic arthritis. Remarkably, acute gout is typically self-limiting, resolving spontaneously within 7-14 days due to multiple counter-regulatory mechanisms (neutrophil apoptosis, macrophage efferocytosis, transforming growth factor-β release, crystal coating with inhibitory proteins). Chronic gout develops after years of untreated hyperuricemia, with progressive crystal accumulation forming macroscopic deposits—tophi—in synovium, bone, cartilage, tendons, bursae, and subcutaneous tissues. Tophi provoke chronic low-grade inflammation, leading to bone erosion, joint deformity, and functional impairment. Clinical presentation occurs along a disease continuum. Asymptomatic hyperuricemia: serum urate elevated without gout flares, tophi, or nephrolithiasis. Acute gouty arthritis: the classic presentation, typically monoarticular at onset. The first metatarsophalangeal joint (podagra) is involved in 50% of first flares and 90% during disease course—its predilection attributed to lower temperature (promoting crystal formation), trauma from weight-bearing, and relatively low pH. Other commonly affected joints include midfoot, ankle, knee, wrist, finger, and elbow. Polyarticular acute gout occurs in 10-20% of patients, particularly those with long-standing disease. Intercritical gout: asymptomatic periods between flares, during which ongoing crystal deposition continues silently. Chronic tophaceous gout: occurs after 10-20 years of untreated hyperuricemia in 30-40% of patients, characterized by persistent polyarthritis, visible tophi (firm, white-yellow, chalky subcutaneous nodules at helix of ear, olecranon bursa, Achilles tendon, finger pulps), and characteristic radiographic erosions with overhanging edges. Urate nephrolithiasis: uric acid stones account for 10% of all kidney stones, associated with persistently acidic urine pH. Chronic urate nephropathy: chronic inflammation and fibrosis from medullary crystal deposition. Diagnosis is definitively established by identification of monosodium urate crystals in synovial fluid or tophus aspirate using compensated polarized light microscopy—needle-shaped, negatively birefringent crystals (yellow when parallel to compensator axis, blue when perpendicular). In resource-limited Zambian settings where microscopy may be unavailable, diagnosis is based on clinical criteria (ACR/EULAR classification criteria, 2018): characteristic podagra, rapid pain onset, erythema, tophus, and hyperuricemia. Serum urate during acute flare may be falsely normal (20% of cases) due to uricosuric effect of inflammation and should be repeated 2-4 weeks after resolution. Synovial fluid analysis also excludes septic arthritis (concurrent gout and sepsis occurs in 2-5%). Radiographs are normal in early disease; chronic findings include well-defined punched-out erosions with sclerotic margins and overhanging edges, typically para-articular, and soft tissue tophi. Ultrasound demonstrates the 'double contour' sign (crystal deposition on articular cartilage surface) and tophi. Dual-energy CT specifically identifies urate deposits. Differential diagnosis includes septic arthritis (requires urgent exclusion via arthrocentesis), pseudogout (calcium pyrophosphate deposition disease—chondrocalcinosis, weakly positive birefringent rhomboid crystals), cellulitis, and other crystal arthropathies. Management is highly effective and potentially curative, yet remains poorly implemented globally. Acute gout management: initiate treatment immediately. First-line: NSAIDs (naproxen, indomethacin, diclofenac) at full anti-inflammatory doses for 5-7 days, with gastroprotection if risk factors. Second-line: colchicine (1.2 mg followed by 0.6 mg one hour later, then 0.6 mg once or twice daily) initiated within 36 hours of flare onset—delayed initiation markedly reduces efficacy. Third-line: glucocorticoids (oral prednisone 30-35 mg daily for 5 days, intra-articular injection for monoarthritis, intramuscular or intravenous for polyarthritis) effective and safe, including in patients with contraindications to NSAIDs/colchicine. Ice packs and rest provide adjunctive relief. Urate-lowering therapy (ULT): indicated for recurrent flares (≥2 per year), tophi, chronic gouty arthritis, nephrolithiasis, or radiographic erosions. The goal is serum urate <6.0 mg/dL (357 μmol/L); <5.0 mg/dL (297 μmol/L) accelerates tophus resolution. Allopurinol is first-line ULT globally and in Zambia—a xanthine oxidase inhibitor, initial dose 100 mg daily (50 mg in stage 4-5 CKD), titrated every 2-4 weeks to target urate. Major hypersensitivity syndrome (DRESS: Drug Reaction with Eosinophilia and Systemic Symptoms) is rare but potentially fatal, associated with HLA-B*5801 allele—high prevalence in sub-Saharan African populations. HLA-B*5801 screening is recommended prior to allopurinol initiation where feasible; if positive or testing unavailable, alternative ULT should be strongly considered. Febuxostat (alternative xanthine oxidase inhibitor) and probenecid (uricosuric) are alternatives but less available in Zambia. ULT is initiated after acute flare resolution and continued indefinitely without interruption—non-adherence is the leading cause of ULT failure. Flare prophylaxis with low-dose colchicine or NSAIDs is essential during the first 3-6 months of ULT, as urate reduction paradoxically triggers flares by mobilizing crystals. Lifestyle modifications: dietary purine restriction (reduce red meat, organ meats, shellfish; avoid high-fructose corn syrup), alcohol limitation (particularly beer and spirits), weight loss, and liberal dairy consumption (uricosuric). Cherries (anthocyanins) may reduce flare risk. Hypertension, diabetes, dyslipidemia, obesity, and chronic kidney disease—frequent comorbidities—require aggressive management. For Zambian clinicians, specific challenges include limited polarized light microscopy for definitive diagnosis, reliance on clinical criteria; high prevalence of HLA-B*5801 and limited availability of screening; competing priorities of HIV/TB management; endemic kidney disease; and need for patient education emphasizing gout as a chronic, treatable disease requiring lifelong ULT—not merely intermittent analgesic therapy. Despite these challenges, allopurinol is inexpensive, widely available, and highly effective when properly dosed and continued. For Zambian nurses and clinicians, comprehensive gout knowledge enables accurate clinical diagnosis of this exquisitely painful but eminently treatable condition, rational selection of acute anti-inflammatory therapy, initiation and titration of allopurinol with appropriate HLA-B*5801 risk counseling, aggressive flare prophylaxis during ULT initiation, patient education emphasizing the chronic disease model and importance of lifelong adherence, and management of associated cardiometabolic comorbidities—transforming gout from a recurrent, debilitating condition to one that is entirely controllable, with prevention of both acute flares and long-term joint damage.
-
Coming soon
Topic 139Coming soon
Systemic Lupus Erythematosus: The Great Imitator
This comprehensive rheumatology topic provides Zambian tertiary nursing and medical students with detailed understanding of systemic lupus erythematosus (SLE)—the prototypical systemic autoimmune disease, characterized by loss of tolerance to nuclear antigens, production of diverse autoantibodies, immune complex deposition, and multi-organ involvement with extraordinarily heterogeneous clinical presentations that have earned it the designation 'the great imitator.' For Zambian healthcare students preparing for examinations in internal medicine, rheumatology, nephrology, dermatology, and immunology, mastery of SLE is essential given its predilection for young women of childbearing age, its increased prevalence and severity in individuals of African ancestry, the diagnostic challenges posed by its mimicry of infectious diseases prevalent in Zambia, and the potential for life-threatening organ involvement requiring prompt recognition and aggressive immunosuppression. The immunopathogenesis of SLE is complex and multifactorial, reflecting intersection of genetic susceptibility, environmental triggers, and stochastic events leading to breakdown of immune tolerance. Genetic factors: SLE heritability is approximately 66%, with multiple susceptibility loci identified. HLA class II alleles (DR2, DR3) confer strongest risk. Complement deficiencies (C1q, C4, C2) are strongly associated—C1q deficiency is the strongest known genetic risk factor. Over 100 non-HLA loci contribute, many involved in innate immunity (IRF5, TLR7, STAT4), adaptive immunity (PTPN22, CTLA4, PD-1), and immune complex clearance (FCGR, ITGAM). The female predominance (9:1) reflects effects of estrogen, X chromosome gene dosage (XX vs XY), and microRNA regulation. Environmental triggers: ultraviolet light (exacerbates cutaneous and systemic disease), Epstein-Barr virus infection (molecular mimicry), cigarette smoking, and certain drugs (hydralazine, procainamide, isoniazid, TNF inhibitors) induce lupus-like autoimmunity. The central immunological defect is loss of tolerance to nuclear antigens, particularly chromatin (DNA-histone complexes) and ribonucleoproteins (Smith, RNP, Ro/SSA, La/SSB). Impaired clearance of apoptotic debris allows accumulation of nuclear autoantigens in extracellular space. Plasmacytoid dendritic cells recognize nucleic acid-containing immune complexes via TLR7 (RNA) and TLR9 (DNA), producing massive quantities of type I interferon (IFN-α, IFN-β)—the 'interferon signature' characteristic of active SLE. Autoreactive B cells escape tolerance checkpoints, producing high-affinity, class-switched autoantibodies. Autoreactive T cells provide help, exhibiting defective regulatory function. Immune complex deposition in tissues (kidney, skin, vessels, choroid plexus) triggers complement activation and Fc receptor-mediated inflammation. Direct antibody-mediated injury (cytopenias) and antibody-mediated cellular dysfunction (neuropsychiatric lupus) contribute. Clinical presentation is extraordinarily heterogeneous, with disease course ranging from mild, episodic cutaneous and articular involvement to rapidly progressive, life-threatening renal, neurologic, and hematologic disease. Constitutional symptoms: fatigue (80-100%), fever (50-80%), weight loss (30-50%)—nonspecific but almost universal. Musculoskeletal: arthralgia/myalgia (>90%), non-erosive symmetric polyarthritis (60-70%) affecting hands, wrists, knees; Jaccoud's arthropathy (reducible deformities from ligamentous laxity); avascular necrosis (10-15%, particularly femoral head, associated with glucocorticoids and vasculitis). Cutaneous: malar rash (30-60%)—fixed erythema over cheeks and nasal bridge, sparing nasolabial folds, often photosensitive; discoid rash (20-30%)—erythematous plaques with follicular plugging, scaling, central atrophy, scarring; subacute cutaneous lupus (10-15%)—annular polycyclic or papulosquamous lesions; photosensitivity (40-60%); oral/nasal ulcers (30-40%)—painless or painful; alopecia (30-50%)—scarring or non-scarring; livedo reticularis, cutaneous vasculitis, Raynaud's phenomenon. Renal: lupus nephritis (30-50%)—major determinant of prognosis. International Society of Nephrology/ Renal Pathology Society classification (Class I-VI) based on kidney biopsy guides therapy. Clinical presentation ranges from asymptomatic hematuria/proteinuria to nephrotic syndrome to rapidly progressive glomerulonephritis. Untreated proliferative nephritis (Class III, IV) progresses to end-stage renal disease. Neuropsychiatric: 12 neurologic and 7 psychiatric syndromes recognized, ranging from common (headache, mood disorders, mild cognitive dysfunction) to rare but severe (seizures, stroke, transverse myelitis, optic neuritis, psychosis). Attributing neuropsychiatric events to SLE versus other causes is often challenging. Cardiovascular: pericarditis (25%), myocarditis, Libman-Sacks endocarditis (sterile vegetations), accelerated atherosclerosis (premature myocardial infarction). Pulmonary: pleuritis (30-50%), pleural effusion, interstitial lung disease, pulmonary hemorrhage, shrinking lung syndrome. Hematologic: anemia of chronic disease, autoimmune hemolytic anemia (10%, Coombs-positive), leukopenia (50%, particularly lymphopenia), thrombocytopenia (25-50%), thrombotic thrombocytopenic purpura-like syndrome. Antiphospholipid syndrome (30%): arterial/venous thrombosis, pregnancy morbidity, livedo reticularis, thrombocytopenia; associated with antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-β2-glycoprotein I). Gastrointestinal: serositis (abdominal pain), vasculitis (ischemia, perforation), pancreatitis, autoimmune hepatitis. Laboratory findings: antinuclear antibodies (ANA) by immunofluorescence on HEp-2 cells—sensitivity 95% but low specificity; positive ANA is entry criterion for classification but not diagnostic. Anti-double-stranded DNA (anti-dsDNA): highly specific (95%) for SLE, correlates with disease activity, particularly nephritis. Anti-Smith (anti-Sm): highly specific (99%) but less sensitive (20-30%). Anti-Ro/SSA and anti-La/SSB: associated with Sjögren's syndrome, subacute cutaneous lupus, neonatal lupus (congenital heart block), photosensitivity. Anti-ribonucleoprotein (anti-RNP): associated with mixed connective tissue disease. Complement levels (C3, C4, CH50): low in active disease, particularly nephritis, due to immune complex consumption. Direct Coombs test: positive in hemolytic anemia. Antiphospholipid antibodies: detected in 30-40%. Urinalysis: proteinuria, hematuria, cellular casts—mandatory at every visit. Kidney biopsy: essential for diagnosis, classification, and treatment guidance in suspected lupus nephritis. Diagnosis: 2019 ACR/EULAR classification criteria—entry criterion is ANA ≥1:80, then additive weighted criteria in seven clinical and three immunologic domains; total score ≥10 classifies SLE. Importantly, classification criteria are not diagnostic criteria; clinical diagnosis remains a nuanced synthesis of history, examination, and serologic findings, with careful exclusion of mimics. Differential diagnosis in Zambian practice is particularly challenging: HIV infection can produce ANA positivity and lupus-like features; tuberculosis may mimic constitutional symptoms and serositis; endemic viral infections (EBV, CMV, parvovirus B19) cause acute polyarthritis and cytopenias; drug-induced lupus from isoniazid (anti-tuberculous therapy) is relevant. Management requires individualized, multidisciplinary approach stratified by disease activity, organ involvement, and severity. General principles: photoprotection (broad-spectrum sunscreen, protective clothing), smoking cessation, cardiovascular risk reduction, vaccination (non-live vaccines), pregnancy planning (high-risk, coordinate with maternal-fetal medicine). Pharmacotherapy is tiered by severity. Mild disease (arthritis, rash, serositis without organ-threatening involvement): hydroxychloroquine (HCQ) is universal—cornerstone of SLE therapy, reduces flares, improves survival, protects against renal and thrombotic events; target dose 5 mg/kg actual body weight; mandatory retinal screening annually after 5 years (risk of retinopathy). NSAIDs for arthritis/serositis (short-term, gastroprotection). Low-dose glucocorticoids (prednisone <7.5 mg/day) for refractory symptoms. Topical glucocorticoids/calcineurin inhibitors for cutaneous disease. Moderate disease (refractory cutaneous/articular, mild hematologic, serositis): methotrexate, azathioprine, mycophenolate mofetil, or belimumab (anti-BLyS) added as steroid-sparing agents. Severe, organ-threatening disease (proliferative nephritis, severe neuropsychiatric, severe hematologic, pulmonary hemorrhage, vasculitis): high-dose glucocorticoids (prednisone 0.5-1 mg/kg/day or pulsed IV methylprednisolone) PLUS cyclophosphamide (NIH regimen or Eurolupus regimen) or mycophenolate mofetil (particularly for nephritis). After induction (3-6 months), transition to maintenance therapy (mycophenolate or azathioprine) with low-dose glucocorticoids. Rituximab (anti-CD20) is effective for refractory disease but limited access. Adjunctive therapies: ACE inhibitors/ARBs for proteinuria; anticoagulation for antiphospholipid syndrome; bisphosphonates for glucocorticoid-induced osteoporosis; antihypertensives, lipid-lowering agents. Prognosis: 5-year survival now exceeds 95% in high-income countries (improved from <50% in 1950s), but remains substantially worse in low-resource settings. Deaths exhibit bimodal distribution: early deaths from active disease (severe nephritis, neuropsychiatric, infections) and late deaths from cardiovascular disease. Poor prognostic factors: male sex, African or Hispanic ancestry, low socioeconomic status, antiphospholipid syndrome, proliferative nephritis, neuropsychiatric involvement, high disease activity scores. For Zambian clinicians, specific challenges include limited availability of diagnostic immunology (anti-dsDNA, anti-Sm, complements), reliance on ANA alone; absence of kidney biopsy pathology services in most centers; high cost and limited availability of steroid-sparing immunosuppressants (mycophenolate, azathioprine, belimumab, rituximab); cyclophosphamide availability but need for appropriate administration and monitoring; competing burden of infectious diseases (HIV, TB) complicating immunosuppression; and need for high index of suspicion for SLE in young women presenting with multisystem disease. Despite these challenges, substantial improvement in outcomes is achievable through early recognition, universal hydroxychloroquine, judicious glucocorticoid use, and context-appropriate immunosuppressive regimens. For Zambian nurses and clinicians, comprehensive SLE knowledge enables recognition of this great imitator in its diverse presentations, appropriate serologic evaluation, assessment of disease activity and organ involvement, stratification of therapy by severity, monitoring for medication toxicity and disease complications, and provision of comprehensive, compassionate care to patients facing a chronic, unpredictable, potentially life-threatening autoimmune disease requiring lifelong multidisciplinary management.
-
Coming soon
Topic 140Coming soon
Spondyloarthritis: Axial and Peripheral
This comprehensive rheumatology topic provides Zambian tertiary nursing and medical students with detailed understanding of the spondyloarthritis (SpA) family—a group of interrelated, chronic inflammatory disorders sharing common genetic predisposition (HLA-B27), clinical features (axial inflammation, asymmetric oligoarthritis, enthesitis, dactylitis), and extra-articular manifestations (acute anterior uveitis, psoriasis, inflammatory bowel disease). For Zambian healthcare students preparing for examinations in internal medicine, rheumatology, orthopaedics, and gastroenterology, mastery of SpA is essential given its substantial prevalence (comparable to rheumatoid arthritis), its frequent misdiagnosis as mechanical back pain leading to diagnostic delays of 5-10 years, its potential for irreversible spinal fusion and disability, and the availability of highly effective therapies including NSAIDs and—in resource-appropriate settings—biologic DMARDs. The spondyloarthritis family includes five interrelated diseases: ankylosing spondylitis (AS, the prototype and most common), psoriatic arthritis (PsA), reactive arthritis (ReA, formerly Reiter's syndrome), arthritis associated with inflammatory bowel disease (IBD-related SpA), and undifferentiated spondyloarthritis (uSpA). These conditions share overlapping clinical features but have distinct associated extra-articular manifestations and management considerations. The immunopathology of SpA is centered on the enthesis—the anatomical site where tendons, ligaments, and joint capsules insert into bone. Enthesitis is the pathognomonic lesion of SpA, distinguishing it from rheumatoid arthritis (synovitis-centered). Mechanical stress at entheseal sites in genetically susceptible individuals triggers an innate immune response mediated by IL-23-producing resident cells (possibly myeloid cells or unconventional T cells). IL-23 activates entheseal-resident T cells (γδ T cells, innate lymphoid cells type 3) to produce IL-17A and IL-22. IL-17A recruits neutrophils, promotes osteoclastogenesis, and drives inflammation. IL-22 stimulates mesenchymal stem cell proliferation and osteoblast differentiation, promoting new bone formation. This IL-23/IL-17 axis is central to SpA pathogenesis, explaining the remarkable efficacy of IL-17 inhibitors. The genetic association with HLA-B27 is the strongest of any MHC-disease association, present in 80-95% of AS patients in Western populations (lower in African populations, ~50-60%). Multiple hypotheses explain HLA-B27 pathogenicity: arthritogenic peptide hypothesis (presentation of unique peptides to CD8+ T cells), misfolding hypothesis (endoplasmic reticulum stress with unfolded protein response, IL-23 induction), and homodimer hypothesis (cell surface B27 heavy chain homodimers recognized by killer immunoglobulin receptors on T cells and NK cells). Non-MHC genetic associations include ERAP1 (involved in peptide trimming for MHC class I, epistatic with HLA-B27), IL23R, and others, reinforcing the IL-23/IL-17 pathway centrality. Clinical presentation encompasses axial disease (sacroiliitis, spondylitis), peripheral arthritis, enthesitis, dactylitis, and extra-articular manifestations. Inflammatory back pain is the cardinal axial symptom, distinguished from mechanical back pain by five features (Calin criteria): age at onset <40 years, insidious onset, improvement with exercise not rest, pain at night (with improvement upon arising), and duration >3 months. Additional features include alternating buttock pain (sacroiliitis), morning stiffness >30 minutes. As disease progresses, syndesmophytes—bony spurs bridging vertebral bodies—form, producing progressive spinal stiffness, reduced range of motion, and ultimately bamboo spine with complete ankylosis. Spinal fractures occur at minimal trauma through ankylosed segments, with high risk of spinal cord injury. Atlantoaxial subluxation and cauda equina syndrome are rare late complications. Peripheral arthritis is typically asymmetric oligoarthritis (≤5 joints), predominantly affecting lower extremities (hips, knees, ankles). Enthesitis presents as localized tenderness at insertions: Achilles tendon, plantar fascia, iliac crest, greater trochanter, tibial tuberosity. Dactylitis ('sausage digit')—diffuse swelling of an entire digit due to flexor tenosynovitis—is highly characteristic of PsA and reactive arthritis. Extra-articular manifestations: acute anterior uveitis (20-30%, typically unilateral, sudden onset, painful, photophobia, recurrent), psoriasis (skin, nail pitting/onycholysis), inflammatory bowel disease (clinically apparent in 5-10%, subclinical gut inflammation in 50-60%). Cardiovascular manifestations: aortic regurgitation (aortitis, aortic root dilation), conduction abnormalities (heart block), increased cardiovascular risk. Pulmonary: apical fibrobullous disease (rare, late complication). Renal: IgA nephropathy, amyloidosis (rare). Diagnosis requires integration of clinical, laboratory, and imaging findings. Assessment of SpondyloArthritis international Society (ASAS) classification criteria exist for axial SpA (imaging arm: sacroiliitis on imaging plus ≥1 SpA feature; clinical arm: HLA-B27 plus ≥2 SpA features) and peripheral SpA (arthritis/enthesitis/dactylitis plus ≥1 SpA feature—uveitis, psoriasis, IBD, preceding infection, HLA-B27, sacroiliitis on imaging). Laboratory findings: no specific diagnostic autoantibodies (RF/ACPA negative—crucial distinction from RA). HLA-B27 testing supports diagnosis but is neither necessary nor sufficient; prevalence in healthy African populations is lower than Caucasians, reducing diagnostic utility. Acute phase reactants (ESR, CRP) elevated in 50-70% but may be normal despite active disease. Synovial fluid is inflammatory (WBC 2,000-50,000, predominantly neutrophils). Imaging: sacroiliitis is the radiographic hallmark. Conventional radiographs demonstrate erosions, sclerosis, ankylosis—but may remain normal for years despite active inflammatory sacroiliitis. MRI with short tau inversion recovery (STIR) sequences detects active inflammation (bone marrow edema) at sacroiliac joints and spine years before radiographic changes, enabling early diagnosis. CT is sensitive for structural damage but exposes to radiation. Ultrasound detects enthesitis and peripheral synovitis. Management requires integrated approach addressing axial, peripheral, and extra-articular disease. Non-pharmacological: patient education, smoking cessation (smoking is strongly associated with worse radiographic progression and functional outcomes), physical therapy (spinal mobility, posture, strengthening exercises), occupational therapy (ergonomic assessment), and exercise (swimming, walking). Pharmacological: first-line for axial disease is NSAIDs (continuous or on-demand)—highly effective for symptom control; no evidence that NSAIDs alter radiographic progression. Analgesics (paracetamol, opioids) for refractory pain. Conventional synthetic DMARDs (methotrexate, sulfasalazine, leflunomide) are ineffective for axial disease but may improve peripheral arthritis. Corticosteroid injections for peripheral arthritis/enthesitis; systemic glucocorticoids are avoided (minimal efficacy, risk of long-term toxicity). Biologic DMARDs are highly effective for axial and peripheral disease, structural progression, and extra-articular manifestations. TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab) are first-line biologics, producing rapid improvement in symptoms, function, and quality of life, and reducing MRI-evident inflammation. IL-17 inhibitors (secukinumab, ixekizumab) are equally effective, particularly for axial disease, and are alternatives after TNF inhibitor failure or contraindications. IL-12/23 inhibitors (ustekinumab) and JAK inhibitors (tofacitinib, upadacitinib) are effective for PsA. In Zambian context, biologic DMARDs are largely inaccessible; management focuses on NSAIDs, physical therapy, sulfasalazine for peripheral arthritis, and corticosteroid injections. Surgical management: total hip arthroplasty for advanced hip involvement; spinal osteotomy for severe kyphotic deformity; spinal fusion for instability. Prognosis: variable. Ankylosing spondylitis is not universally progressive; some patients have mild disease without significant functional impairment. Poor prognostic factors include: hip involvement, elevated acute phase reactants, persistent active disease, smoking, presence of syndesmophytes at baseline, and non-response to NSAIDs. Mortality is increased (standardized mortality ratio 1.5-2.0), primarily from cardiovascular disease. For Zambian clinicians, specific challenges include low awareness among primary care providers leading to prolonged diagnostic delays, misdiagnosis as mechanical back pain or tuberculosis spondylitis, limited access to MRI for early diagnosis, low prevalence and reduced diagnostic utility of HLA-B27 in African populations, and lack of access to biologic DMARDs. Despite these challenges, substantial improvement in patient outcomes is achievable through high index of suspicion for inflammatory back pain in young adults, appropriate use of plain radiography for sacroiliitis, aggressive NSAID therapy, physical therapy, smoking cessation counseling, and appropriate surgical referral. For Zambian nurses and clinicians, comprehensive SpA knowledge enables recognition of inflammatory back pain and its distinction from mechanical causes, identification of the characteristic extra-articular manifestations (uveitis, psoriasis, IBD), appropriate imaging and laboratory evaluation, initiation and monitoring of NSAID therapy, coordination of physical and occupational therapy, smoking cessation intervention, and timely surgical referral—ultimately reducing the diagnostic odyssey and preventing the irreversible spinal fusion and disability that characterizes this still-underrecognized group of inflammatory rheumatic diseases.
-
Coming soon
Topic 141Coming soon
Septic Arthritis
Septic arthritis is an orthopaedic emergency—acute infection of synovial joint causing rapid, irreversible cartilage destruction within hours. For Zambian students, critical for emergency medicine, paediatrics, and orthopaedics. Pathophysiology: haematogenous seeding (most common), direct inoculation, contiguous spread. Bacteria proliferate in synovial fluid (excellent culture medium, low opsonins). Neutrophil infiltration → proteolytic enzymes (MMPs, cathepsins) degrade aggrecan, type II collagen. Intra-articular pressure increases → synovial ischaemia → chondrocyte death. IRREVERSIBLE cartilage loss, subchondral erosion, joint destruction. Pathogens: Staphylococcus aureus (40-70%, MRSA increasing). Neisseria gonorrhoeae (sexually active young adults, tenosynovitis, dermatitis). Kingella kingae (young children 6m-4y). Gram-negative (elderly, immunocompromised). Salmonella (sickle cell). Clinical: ACUTE onset (<48 hours). Fever, joint pain, swelling, warmth, effusion. EXQUISITE pain with passive motion (most sensitive sign). Knee (50%), hip, shoulder, ankle, wrist. Gonococcal: migratory polyarthralgia, tenosynovitis, pustular skin lesions. Neonate/elderly/immunocompromised: may have minimal systemic signs. Diagnosis: ARTHROCENTESIS MANDATORY. Synovial fluid WBC >50,000/mm³ (often >100,000), >90% neutrophils. Gram stain (+) 50-75% nongonococcal, <25% gonococcal. Culture (+) 70-90% nongonococcal. Blood cultures (+) 30-50%. ESR/CRP elevated. Radiographs: normal early, effusion (widened joint space in children). Ultrasound: effusion, guide arthrocentesis (hip). MRI: synovial enhancement, effusion, osteomyelitis/abscess. Management: EMERGENCY. IV antibiotics immediately after cultures—empiric: vancomycin + 3rd-gen cephalosporin (MRSA cover), 3rd-gen cephalosporin alone (gonococcal). Duration: 3-4 weeks (2 weeks IV + 1-2 weeks oral highly bioavailable). SURGICAL DRAINAGE URGENT: arthroscopic/open lavage and debridement—evacuate purulent material, reduce bacterial/enzyme load, decompress joint. Hip (especially child): emergent open drainage (avascular necrosis risk). Daily passive ROM post-op. Prognosis: delayed treatment >48 hours = poor outcome. Diagnosis within 24-48 hours = good recovery. Zambian context: HIV-associated septic arthritis (atypical organisms, presentation). Limited arthrocentesis access, orthopaedic surgical capacity. High index suspicion essential. Prevention: prompt STI treatment (gonococcal), appropriate penetrating joint injury management.
-
Coming soon
Topic 142Coming soon
Gout
Gout is the most common inflammatory arthritis—caused by monosodium urate crystal deposition in hyperuricaemia. For Zambian students, increasingly prevalent with nutritional transition, obesity, CKD. Pathophysiology: hyperuricaemia (>6.8mg/dL, saturation point) → crystal formation. Precipitants: rapid urate fluctuation, trauma, cooling, dehydration. Crystals activate NLRP3 inflammasome → IL-1β → neutrophil recruitment → acute inflammation. Self-limited (7-14 days): neutrophil apoptosis, TGF-β, crystal coating. Chronic untreated hyperuricaemia → tophi (macroscopic crystal deposits), bone erosion, joint deformity. Clinical: ACUTE: rapid onset (peak 12-24h), EXCRUCIATING pain, erythema, warmth, swelling. PODAGRA (1st MTP) 50% first flare, 90% lifetime. Midfoot, ankle, knee, wrist, finger, elbow. Polyarticular: 10-20%, long-standing disease. INTERCRITICAL: asymptomatic periods, ongoing crystal deposition. CHRONIC TOPHACEOUS: 10-20 years untreated, persistent polyarthritis, visible tophi (firm, white-yellow, chalky—helix of ear, olecranon, Achilles, finger pulps), characteristic erosions (overhanging edges). Urate nephrolithiasis, chronic urate nephropathy. Diagnosis: GOLD STANDARD—polarized light microscopy of synovial fluid/tophus aspirate: NEEDLE-SHAPED, NEGATIVELY BIREFRINGENT crystals (yellow parallel, blue perpendicular). Clinical diagnosis (ACR/EULAR criteria): podagra, rapid onset, erythema, tophus, hyperuricaemia. Serum urate NORMAL during acute flare in 20% (uricosuric effect of inflammation)—repeat 2-4 weeks post-resolution. Radiographs: normal early; chronic: punched-out erosions with sclerotic margins, overhanging edges, soft tissue tophi. Ultrasound: double contour sign (crystal deposition on cartilage). DECT: specific urate identification. Differential: septic arthritis (EXCLUDE by arthrocentesis), pseudogout (CPPD—chondrocalcinosis, weakly positive birefringent rhomboid crystals). Management: ACUTE: initiate IMMEDIATELY. NSAIDs (naproxen, indomethacin, diclofenac) full dose 5-7 days + gastroprotection. Colchicine (1.2mg then 0.6mg 1h later, then 0.6mg 1-2x daily) within 36 hours—delayed = ineffective. Glucocorticoids (oral prednisone 30-35mg 5 days, intra-articular, IM/IV)—safe with contraindications to NSAIDs/colchicine. Ice, rest. URATE-LOWERING THERAPY (ULT): Indicated: ≥2 flares/year, tophi, chronic arthritis, nephrolithiasis, radiographic erosions. Goal: serum urate <6.0mg/dL (<5.0mg/dL for tophus resolution). ALLOPURINOL: first-line, xanthine oxidase inhibitor. Start 100mg daily (50mg CKD stage 4-5), titrate q2-4 weeks to target. HLA-B*5801 screening recommended (high prevalence sub-Saharan Africa)—DRESS syndrome risk. If positive or unavailable: febuxostat, probenecid (alternatives). ULT initiated AFTER flare resolution, CONTINUED INDEFINITELY. FLARE PROPHYLAXIS mandatory first 3-6 months ULT: low-dose colchicine or NSAID. Lifestyle: dietary purine restriction (red meat, organ meat, shellfish, high-fructose corn syrup), alcohol limitation (beer, spirits), weight loss, dairy consumption (uricosuric). Cherries (anthocyanins) reduce flare risk. Comorbidity management: hypertension, diabetes, dyslipidaemia, obesity, CKD. Zambian context: allopurinol inexpensive, widely available; HLA-B*5801 screening limited; emphasis on clinical diagnosis, patient education—gout is CHRONIC, treatable, requires LIFELONG ULT, not intermittent analgesic therapy.
-
Coming soon
Topic 143Coming soon
Calcium Pyrophosphate Deposition Disease
Calcium pyrophosphate deposition (CPPD) disease—pseudogout—is crystal arthropathy caused by CPP crystal deposition in cartilage (chondrocalcinosis), with acute inflammatory flares mimicking gout. For Zambian students, important differential diagnosis in older adults. Pathophysiology: CPP crystals form in cartilage matrix, increased with aging, osteoarthritis, metabolic disorders (haemochromatosis, hyperparathyroidism, hypomagnesemia, hypophosphatasia). Crystal shedding triggers NLRP3 inflammasome → IL-1β → neutrophil recruitment → acute synovitis. Clinical presentations: ACUTE CPP CRYSTAL ARTHRITIS (pseudogout): acute, severe monoarthritis—knee MOST COMMON (50%), wrist, shoulder, ankle, elbow. Self-limited 7-14 days. ASYMPTOMATIC CHONDROCALCINOSIS: incidental radiographic finding. OSTEOARTHRITIS WITH CPPD: accelerated OA with atypical distribution (wrist, MCP, glenohumeral). CHRONIC CPP INFLAMMATORY ARTHRITIS: symmetric polyarthritis mimicking RA. Diagnosis: SYNOVIAL FLUID ANALYSIS: positively birefringent, rhomboid-shaped crystals (blue parallel, yellow perpendicular compensator). Radiographs: chondrocalcinosis—linear, punctate calcification in fibrocartilage (menisci, triangular fibrocartilage), hyaline cartilage (knee, wrist). Associated conditions: primary hyperparathyroidism (screen calcium, PTH), haemochromatosis (ferritin, transferrin saturation), hypomagnesemia, hypophosphatasia. Management: ACUTE: NSAIDs, colchicine, intra-articular corticosteroids, systemic glucocorticoids (similar to gout). CHRONIC: low-dose colchicine or NSAID prophylaxis for recurrent flares. Treat underlying metabolic disorder. No equivalent of urate-lowering therapy—crystals cannot be dissolved. Prognosis: self-limited acute episodes; chronic arthropathy may progress. Zambian context: consider in elderly with acute knee arthritis, chondrocalcinosis on radiograph; distinguish from septic arthritis (arthrocentesis essential); limited synovial fluid analysis access—clinical-radiographic diagnosis.
-
Coming soon
Topic 144Coming soon
Ankylosing Spondylitis
Ankylosing spondylitis (AS) is the prototype spondyloarthritis—chronic inflammatory disease primarily affecting axial skeleton, causing sacroiliitis, spondylitis, and progressive spinal fusion. For Zambian students, frequently misdiagnosed as mechanical back pain; diagnostic delay 5-10 years common. Pathophysiology: genetic (HLA-B27 80-95% in Caucasians, 50-60% African populations), IL-23/IL-17 axis. Enthesitis—inflammation at tendon/ligament insertion into bone—is pathognomonic. Mechanical stress at entheses in genetically susceptible → IL-23 from resident myeloid cells → IL-17 from γδ T cells, ILC3 → neutrophil recruitment, osteoclastogenesis (inflammation) AND IL-22 → mesenchymal proliferation, osteoblast differentiation (new bone formation). Result: inflammatory bone erosion followed by reparative new bone formation—SYNDESMOPHYTES (bony bridges between vertebrae), ANKYLOSIS (spinal fusion). Clinical: INFLAMMATORY BACK PAIN (Calin criteria): onset <40 years, insidious, >3 months, morning stiffness >30 minutes, improvement with exercise NOT rest, night pain (improves with rising). ALTERNATING BUTTOCK PAIN (sacroiliitis). Progressive spinal stiffness, reduced range of motion (Schober test, chest expansion). Bamboo spine: complete ankylosis, rigid kyphosis. Spinal fractures: minimal trauma through ankylosed segments, high cord injury risk. Atlantoaxial subluxation, cauda equina syndrome (rare late). PERIPHERAL: asymmetric oligoarthritis (lower extremity predominant), enthesitis (Achilles, plantar fascia), dactylitis. EXTRA-ARTICULAR: acute anterior uveitis (20-30%, unilateral, sudden, painful, photophobia, recurrent), psoriasis, IBD (clinical 5-10%, subclinical gut inflammation 50-60%). Cardiovascular: aortitis, aortic regurgitation, conduction abnormalities. Pulmonary: apical fibrobullous disease (rare late). Diagnosis: RADIOGRAPHY—sacroiliitis: erosions, sclerosis, ankylosis. MRI with STIR: bone marrow edema (active sacroiliitis) years before radiographic changes. HLA-B27 supports diagnosis (lower utility in African populations). ESR/CRP elevated 50-70% (may be normal despite active disease). ASAS classification criteria: imaging arm (sacroiliitis on imaging + ≥1 SpA feature) OR clinical arm (HLA-B27 + ≥2 SpA features). Management: NON-PHARMACOLOGICAL: patient education, smoking cessation (STRONGLY associated with worse radiographic progression, function), physical therapy (spinal mobility, posture, strengthening), exercise (swimming, walking). PHARMACOLOGICAL: NSAIDs first-line—highly effective symptom control (no evidence halts radiographic progression). Analgesics for refractory pain. csDMARDs (methotrexate, sulfasalazine) INEFFECTIVE for axial disease (may help peripheral arthritis). Corticosteroid injections for peripheral/entheseal; systemic glucocorticoids avoided (minimal efficacy, long-term toxicity). BIOLOGIC DMARDs: TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab)—rapid symptom improvement, reduced MRI inflammation, MAY slow radiographic progression. IL-17 inhibitors (secukinumab, ixekizumab) equally effective. In Zambia: largely inaccessible. SURGICAL: total hip arthroplasty (advanced hip involvement), spinal osteotomy (severe kyphotic deformity), spinal fusion (instability). Prognosis: variable—not universally progressive. Poor prognostic factors: hip involvement, elevated acute phase reactants, persistent active disease, smoking, syndesmophytes at baseline, NSAID non-response. Mortality increased (SMR 1.5-2.0), primarily cardiovascular. Zambian context: low awareness, diagnostic delay, limited MRI access, lower HLA-B27 prevalence reduces diagnostic utility, biologic DMARDs unavailable. Emphasis: high index suspicion for inflammatory back pain in young adults, plain radiography sacroiliitis, NSAIDs, physical therapy, smoking cessation.